Brokerages Set Johnson & Johnson (NYSE:JNJ) Price Target at $233.73

Johnson & Johnson (NYSE:JNJ) has received an average rating of “Moderate Buy” from the twenty-six ratings firms that are currently covering the company, Marketbeat Ratings reports. Eight equities research analysts have rated the stock with a hold recommendation, seventeen have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $233.7273.

Several analysts recently issued reports on JNJ shares. Guggenheim upped their price objective on shares of Johnson & Johnson from $227.00 to $240.00 and gave the company a “buy” rating in a research note on Friday, January 23rd. Bank of America upped their price target on Johnson & Johnson from $220.00 to $221.00 and gave the company a “neutral” rating in a research report on Thursday, January 22nd. Argus lifted their price objective on Johnson & Johnson from $210.00 to $240.00 in a research report on Friday, January 23rd. Johnson Rice set a $190.00 target price on Johnson & Johnson and gave the company a “hold” rating in a report on Wednesday, October 22nd. Finally, Daiwa Securities Group raised their target price on Johnson & Johnson from $203.00 to $237.00 and gave the stock an “outperform” rating in a research note on Thursday, January 29th.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Announced a >$1 billion investment to build a next‑generation cell‑therapy manufacturing facility in Pennsylvania as part of a multi‑year U.S. manufacturing expansion, signaling long‑term capacity growth for its biologics/cell therapy pipeline. Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania
• Positive Sentiment: FDA approved a simplified monthly dosing schedule for RYBREVANT FASPRO (amivantamab + hyaluronidase), improving convenience for EGFR+ NSCLC patients and potentially boosting uptake and product competitiveness. FDA approves RYBREVANT FASPRO as the only EGFR-targeted therapy that can be administered once a month
• Positive Sentiment: Received FDA Breakthrough Therapy Designation for subcutaneous amivantamab (RYBREVANT FASPRO) in advanced head & neck cancer — a regulatory accelerator that can shorten development timelines and enhance commercial prospects if confirmatory data follow. RYBREVANT FASPRO receives U.S. FDA Breakthrough Therapy Designation for head and neck cancer
• Positive Sentiment: Reinforced shareholder returns with a quarterly dividend increase (quarterly payout raised to $1.30), supporting JNJ’s income appeal and dividend‑investor base. Verizon vs Johnson & Johnson: Which Dividend Hike Winner Is the Better Buy?
• Neutral Sentiment: Options activity has picked up interest around JNJ, which can amplify near‑term moves but doesn’t by itself change fundamentals. Watch for large/ directionally concentrated trades. Behind the Scenes of Johnson & Johnson’s Latest Options Trends
• Neutral Sentiment: Street attention and analyst writeups (Zacks, TipRanks) are keeping JNJ in the spotlight; useful for sentiment tracking but incremental to fundamental drivers. Johnson & Johnson (JNJ) Is a Trending Stock
• Neutral Sentiment: A small contract extension with Trellus Health keeps an adherence/support program in place; operationally positive but immaterial to JNJ’s top line. Trellus Health shares double on J&J extension
• Negative Sentiment: Ongoing talc litigation and recent verdict coverage continue to highlight legal risk and valuation uncertainty, which can cap multiple expansion despite operational positives. Johnson And Johnson Talc Verdict Puts Legal Risks And Valuation In Focus

Insider Activity

In related news, EVP Timothy Schmid sold 22,623 shares of the stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the completion of the transaction, the executive vice president owned 26,769 shares of the company’s stock, valued at approximately $6,540,469.77. This trade represents a 45.80% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Vanessa Broadhurst sold 6,197 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the completion of the sale, the executive vice president owned 23,003 shares of the company’s stock, valued at $5,598,700.17. This trade represents a 21.22% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.16% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Sierra Capital LLC grew its stake in shares of Johnson & Johnson by 0.5% during the fourth quarter. Sierra Capital LLC now owns 8,144 shares of the company’s stock worth $1,685,000 after purchasing an additional 41 shares in the last quarter. Broadleaf Partners LLC boosted its position in shares of Johnson & Johnson by 0.6% during the 4th quarter. Broadleaf Partners LLC now owns 7,348 shares of the company’s stock worth $1,521,000 after acquiring an additional 43 shares in the last quarter. Jessup Wealth Management Inc boosted its position in shares of Johnson & Johnson by 0.6% during the 4th quarter. Jessup Wealth Management Inc now owns 7,574 shares of the company’s stock worth $1,567,000 after acquiring an additional 44 shares in the last quarter. Plancorp LLC raised its position in shares of Johnson & Johnson by 0.3% during the 4th quarter. Plancorp LLC now owns 15,889 shares of the company’s stock worth $3,288,000 after acquiring an additional 45 shares in the last quarter. Finally, Baron Silver Stevens Financial Advisors LLC lifted its stake in Johnson & Johnson by 0.8% during the fourth quarter. Baron Silver Stevens Financial Advisors LLC now owns 5,645 shares of the company’s stock worth $1,168,000 after purchasing an additional 45 shares during the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Up 0.6%

NYSE JNJ opened at $244.89 on Monday. The business has a fifty day moving average price of $219.71 and a 200 day moving average price of $198.21. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.77 and a current ratio of 1.03. The company has a market cap of $590.17 billion, a P/E ratio of 22.16, a P/E/G ratio of 2.36 and a beta of 0.35. Johnson & Johnson has a one year low of $141.50 and a one year high of $246.35.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. The business had revenue of $24.28 billion during the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. Research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.1%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio is 47.06%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.